BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

Phase 1

Completed

Conditions: Advanced Solid Tumor
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Bapotulimab (BAY1905254)
Drug: Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)

First Posted Date: 2018-09-11

Last Posted Date: 2024-05-28

Lead Sponsor: Bayer

Target Recruit Count: 60

Registration Number: NCT03666273

Locations: 🇺🇸
South Texas Accelerated Research Therapeutics | START San Antonio, San Antonio, Texas, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States

and more 5 locations

Effect of Copanlisib on Metformin Pharmacokinetics and Pharmacodynamics

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Copanlisib (Aliqopa, BAY80-6946)
Drug: Metformin

First Posted Date: 2018-08-31

Last Posted Date: 2020-01-28

Lead Sponsor: Bayer

Target Recruit Count: 13

Registration Number: NCT03655301

Locations: 🇺🇸
Pharmaceutical Product Development (PPD), LLC, Austin, Texas, United States

Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment

Terminated

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)
Drug: Sorafenib (Nexavar, BAY43-9006)

First Posted Date: 2018-08-23

Last Posted Date: 2020-08-21

Lead Sponsor: Bayer

Target Recruit Count: 3

Registration Number: NCT03644511

Locations: 🇩🇪
Many Locations, Multiple Locations, Germany

Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied

Phase 3

Completed

Conditions: Glaucoma, Neovascular

Interventions: Drug: Aflibercept (EYLEA, BAY86-5321)
Drug: Topical IOP-lowering drugs

First Posted Date: 2018-08-21

Last Posted Date: 2020-03-03

Lead Sponsor: Bayer

Target Recruit Count: 16

Registration Number: NCT03639675

Locations: 🇯🇵
University of Fukui Hospital, Yoshida, Fukui, Japan
🇯🇵
Kanazawa University Hospital, Kanazawa, Ishikawa, Japan
🇯🇵
Shimane University Hospital, Izumo, Shimane, Japan

and more 4 locations

Study on the Risk of Allergy-like Reactions After Intra-arterial or Intra-venous Injection of the Marketed X-ray Contrast Medium Iopromid

Completed

Conditions: Contrast Medium

Interventions: Drug: Iopromide (Ultravist, BAY86-4877)

First Posted Date: 2018-08-09

Last Posted Date: 2020-02-17

Lead Sponsor: Bayer

Target Recruit Count: 133331

Registration Number: NCT03622801

Locations: 🇩🇪
Many Locations, Multiple Locations, Germany

Study to Develop a Tool to Estimate the Kidney Function in Databases Without Laboratory Data

Completed

Conditions: Renal Function

Interventions: Other: No Intervention

First Posted Date: 2018-07-30

Last Posted Date: 2019-12-10

Lead Sponsor: Bayer

Target Recruit Count: 5132200

Registration Number: NCT03605810

Locations: 🇺🇸
US OPTUM CDM database, Whippany, New Jersey, United States

Study to Evaluate How Patients Regard the Benefits and Risks of Low-dose Aspirin for the Prevention of Heart and Blood Vessels Disease and for the Prevention of Cancer of the Colon and Rectum

Completed

Conditions: Cardiovascular Disease
Colorectal Cancer

Interventions: Drug: Acetylsalicylic acid (Aspirin, BAYE4465)

First Posted Date: 2018-07-27

Last Posted Date: 2020-10-05

Lead Sponsor: Bayer

Target Recruit Count: 1028

Registration Number: NCT03603366

Locations: 🇮🇹
Many locations, Multiple Locations, Italy

Obstructive Sleep Apnea (OSA) Treated With a Potassium Channel Inhibitor

Phase 2

Completed

Conditions: Sleep Apnea, Obstructive

Interventions: Drug: BAY2253651
Drug: Placebo

First Posted Date: 2018-07-27

Last Posted Date: 2020-12-11

Lead Sponsor: Bayer

Target Recruit Count: 34

Registration Number: NCT03603678

Locations: 🇬🇧
Oxford University Hospitals, Oxford, United Kingdom
🇨🇭
University Hospital Zürich, Zürich, Switzerland

Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry

Terminated

Conditions: Hemophilia A

Interventions: Drug: New FVIII products

First Posted Date: 2018-07-27

Last Posted Date: 2022-08-25

Lead Sponsor: Bayer

Target Recruit Count: 3

Registration Number: NCT03603275

Locations: 🇺🇸
Emory / Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Boston Hemophilia Center at Children's Hospital of Boston/Brigham Women's, Boston, Massachusetts, United States
🇺🇸
Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States

and more 24 locations

Study on the Safety of the Approved Product Empedic L Cream During Its Routine Use (Active Ingredient is Clotrimazole 1%)

Completed

Conditions: Vaginal Candida

Interventions: Drug: Clotrimazole 1% (Empecid L Cream, BAYB5097)

First Posted Date: 2018-07-26

Last Posted Date: 2022-07-22

Lead Sponsor: Bayer

Target Recruit Count: 1033

Registration Number: NCT03599323

Locations: 🇯🇵
Many Locations, Multiple Locations, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy